JOANNA YI

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA06/2013Pediatric Hematology/Oncology
    University of Minnesota Pediatrics Department, Minneapolis, MN06/2010Pediatrics Residency
    University of Wisconsin-Madison School of Medicine and Public Health, Madison, WIMD05/2007Medicine
    University of Wisconsin-Madison, Madison, WIBS05/2003Pharmacology/Toxicology
    Collapse awards and honors
    2008 - 2008Norma K. C. Ramsey Award of Excellence for the Most Outstanding Resident in Pediatric Heme/Onc/BMT, University of Minnesota Pediatrics Department
    2010 - 2010Susan Vincent Outstanding Resident Teaching Award, University of Minnesota Pediatrics Department
    2012 - 2017Loan Repayment Program, NIH
    2014 - 2014Abstract Achievement Award, American Society of Hematology
    2018 - 2018Methods in Clinical Cancer Research Vail Workshop, AACR/ASCO

    Collapse Overview 
    Collapse overview
    Dr. Joanna Yi is a member of Texas Children's Cancer Center's Developmental Therapeutics and Leukemia Teams. Her translational research focuses on the pre-clinical identification and development of new, targeted small molecules for the treatment of childhood cancers with the purpose of evaluating them in early phase clinical trials. She is especially interested in epigenetic drugs and combining them with other active agents.

    Dr. Yi wants to discover new, less toxic, targeted drugs by combining the translational drug discovery techniques of the Center for Drug Discovery at Baylor College of Medicine, with the clinical developmental therapeutics program of Texas Children’s Cancer and Hematology Centers. In the laboratory, Dr. Yi is working with TCH and BCM investigators in the cancer center to identify and characterize small molecules with clinical promise in challenging pediatric cancers. She also is developing tests of “on-target” effect of these compounds to be used in clinical trials and evaluating the targeted small molecules in combination with other active agents to identify the best combinations to move forwards to clinical trials. Her lab is also studying the transcriptional control of pediatric leukemias to find new, druggable targets.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Perez MW, Sias-Garcia O, Daramola A, Wei H, Terrell M, Rashid R, Park WD, Duong K, Horton TM, Li F, Cherayil N, Koren JV, Gant VU, Junco JJ, Curry CV, Stevens AM, Lin CY, Yi JS. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency. Blood Adv. 2021 Dec 14; 5(23):4864-4876. PMID: 34543389.
      Citations:    Fields:    
    2. McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver NG, Kadia TM, DiNardo CD, Yi JS, Cuglievan B. Gilteritinib Combination Therapies in Pediatric Patients with FLT3 Mutated Acute Myeloid Leukemia. Blood Adv. 2021 Sep 30. PMID: 34592761.
      Citations:    Fields:    
    3. Yi JS, Sias-Garcia O, Nasholm N, Hu X, Iniguez AB, Hall MD, Davis M, Guha R, Moreno-Smith M, Barbieri E, Duong K, Koach J, Qi J, Bradner JE, Stegmaier K, Weiss WA, Gustafson WC. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633. PMID: 34107377.
      Citations:    Fields:    
    4. Pearson AD, DuBois SG, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, Bennett K, Bourdeaut F, Brown PA, Chesler L, Clymer J, Fox E, French CA, Germovsek E, Giles FJ, Bender JG, Hattersley MM, Ludwinski D, Luptakova K, Maris J, McDonough J, Nikolova Z, Smith M, Tsiatis AC, Vibhakar R, Weiner S, Yi JS, Zheng F, Vassal G. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021 03; 146:115-124. PMID: 33601323.
      Citations:    Fields:    Translation:Humans
    5. Yi JS, Kamihara J, Kesselheim JC, Davies K, van Hoff J, Silverman LB, Mullen EA. Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer. 2017 05; 64(5). PMID: 27862952.
      Citations:    Fields:    Translation:Humans
    6. Green AL, Yi J, Bezler N, Pikman Y, Tubman VN, Obeng EA, O'Neil T, Mersereau R, Morrissey L, Billett AL. A Prospective Cohort Quality Improvement Study to Reduce the Time to Antibiotics for New Fever in Neutropenic Pediatric Oncology Inpatients. Pediatr Blood Cancer. 2016 Jan; 63(1):112-7. PMID: 26292080.
      Citations:    Fields:    Translation:Humans
    7. Yi JS, Federation AJ, Qi J, Dhe-Paganon S, Hadler M, Xu X, St Pierre R, Varca AC, Wu L, Marineau JJ, Smith WB, Souza A, Chory EJ, Armstrong SA, Bradner JE. Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol. 2015 Mar 20; 10(3):667-74. PMID: 25397901.
      Citations: 6     Fields:    Translation:HumansCells
    8. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira M. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012; 3:1288. PMID: 23250418.
      Citations: 111     Fields:    Translation:HumansCells
    9. Serra A, Brozoski D, Simeon T, Yi J, Bastasic J, Franciosi R, Jacobs ER, Forster HV. Serotonin and serotonin receptor expression in the aorta of carotid intact and denervated newborns. Respir Physiol Neurobiol. 2002 Sep 04; 132(3):253-64. PMID: 12208084.
      Citations: 2     Fields:    Translation:Animals
    YI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (64)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _